title: Simultaneous hybrid revascularization by carotid stenting and coronary artery bypass grafting: the SHARP study.
abstract: OBJECTIVE
  In an attempt to reduce post-operative events we investigated a new therapeutic strategy consisting of a simultaneous hybrid revascularization by carotid artery stenting (CAS), immediately followed by an on-pump coronary artery bypass graft (CABG).
  
  
  BACKGROUND
  Preventing stroke and cardiovascular events after coronary artery revascularization in patients with elevated surgical risk is a complex and multifaceted problem.
  
  
  METHODS
  One hundred-one consecutive patients with severe carotid and coronary artery disease and a standard EuroSCORE >or=5 were included in this multicenter study. Immediately after CAS, patients underwent CABG. The primary end point was the incidence of stroke, acute myocardial infarction (AMI), or death at 30 days. Secondary outcomes were transient ischemic attacks; major local complications; bleeding and systemic complications within 30 days after treatment; and any stroke, AMI, or death occurring from the 31st day to the end of the 12-month follow-up. All clinical outcomes were assessed by an independent monitoring board.
  
  
  RESULTS
  The rate of procedural success was 98%. The 30-day cumulative incidence of disabling stroke, AMI, or death was 4%: 2 patients died (2%) in the post-operative period, and 2 patients (2%) had a stroke immediately after CAS and before CABG. Three patients died from the 31st day to the 12th month after the procedure.
  
  
  CONCLUSIONS
  Our findings indicate that in high-risk patients with coronary artery disease suitable for CABG and carotid artery disease, the hybrid revascularization by CAS immediately followed by CABG is a promising and feasible therapeutic strategy.
authors.affiliation: Divisione di Cardiologia, Università Tor Vergata, Rome, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Versaci
authors.forename: Bernhard
authors.initials: B
authors.lastname: Reimers
authors.forename: Costantino
authors.initials: C
authors.lastname: Del Giudice
authors.forename: Joachim
authors.initials: J
authors.lastname: Schofer
authors.forename: Alessandro
authors.initials: A
authors.lastname: Giacomin
authors.forename: Salvatore
authors.initials: S
authors.lastname: Saccà
authors.forename: Roberto
authors.initials: R
authors.lastname: Gandini
authors.forename: Remo
authors.initials: R
authors.lastname: Albiero
authors.forename: Antonio
authors.initials: A
authors.lastname: Pellegrino
authors.forename: Fabio
authors.initials: F
authors.lastname: Bertoldo
authors.forename: Giovanni
authors.initials: G
authors.lastname: Simonetti
authors.forename: Luigi
authors.initials: L
authors.lastname: Chiariello
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D002339:Carotid Arteries; D002340:Carotid Artery Diseases / Q000188:drug therapy / Q000628:therapy*; D000077144:Clopidogrel; D047549:Coronary Artery Bypass, Off-Pump; D003324:Coronary Artery Disease / Q000473:pathology* / Q000601:surgery; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011446:Prospective Studies; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D013997:Time Factors; D014057:Tomography, X-Ray Computed
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine